The allegations surrounding Ultragenyx demonstrate the AKS issues within arrangements that, to many, are difficult to envision as being referrals.
Tag: pharmaceutical
A physician has been indicted for his role in a compound pharmacy prescription scam that included disguised kickbacks. Lots of lessons here.
Ride along with Mark as he discusses the danger of intentionally or negligently allowing someone else to use your medical license.
In general terms, the federal Anti-Kickback Statute (“AKS”) prohibits the offer, demand, payment, and acceptance of remuneration—that is, of anything of value—for referrals.
But what about the rising price of settling allegations of pharmaceutical price-fixing?
The speed limit’s 70 mph. I’m not going to tell you how fast I’m going, but I’m going with the flow of traffic, which is traveling at a lot more than the speed limit. Would a defense of, “but everyone is speeding” actually work?
Compounding pharmaceuticals, specific drugs for specific patients, offers tremendous benefit. The problems arise when the benefit is for the prescribing physician.
Former CEO Michael Babich pleaded guilty last week to charges related to the plethora of kickback allegations surrounding Insys Therapeutics, Inc., and its fentanyl drug, Subsys.
U.S. Government Intervenes in 5 Kickback Based Whistleblower Cases Against Insys – Success in Motion
Ride along while Mark discusses the expanding case involving Insys Therapeutics and kickbacks paid to induce prescription of its drug, Subsys.
The federal Anti-Kickback statute makes it illegal to receive anything of value for the referral of federal health care program patients. How are you managing this potential pitfall?